Michael Dickinson is a globally recognised expert in the management of lymphoma, particularly diffuse large B-cell lymphoma. mantle cell lymphoma and Hodgkin lymphoma. He was the lead Australian investigator on the pivotal ELARA, BELINDA and Zuma 7 trials of CAR-T cell therapies, and has led the first in-human trials of the rapid CAR-T YTB323 as well as CAR-NK treatment. He helped establish standard CAR-T treatment in Australia and is the deputy lead of the CAR-T service at Peter Mac. He was the global lead investigator on the registration study of the bispecific antibody glofitamab that led to registration of that drug in over sixty countries. He has been the lead or senior author of publications in New England Journal of Medicine, Journal of Clinical Oncology, and Blood, and, as Lead of Aggressive Lymphoma at Peter MacCallum Cancer Centre, believes in trial-led, patient-focussed care.